Posted by Michael Wonder on 17 Dec 2020
FDA approves Amgen's Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab)
17 December 2020 - Fifth FDA Approval From Amgen's Biosimilars Portfolio.
Amgen today announced that the U.S. FDA has approved Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab), for the treatment of adult patients with non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, granulomatosis with polyangiitis (Wegener's Granulomatosis) and microscopic polyangiitis.
Riabni will be made available in the U.S. in January 2021.
